The investigational fungal Cyp51 inhibitor VT-1129 demonstrates potent in vitro activity against cryptococcus neoformans and cryptococcus gattii

Shawn R. Lockhart, Annette W. Fothergill, Naureen Iqbal, Carol B. Bolden, Nina T. Grossman, Edward P. Garvey, Stephen R. Brand, William J. Hoekstra, Robert J. Schotzinger, Elizabeth Ottinger, Thomas F. Patterson, Nathan P. Wiederhold

Producción científica: Articlerevisión exhaustiva

54 Citas (Scopus)

Resumen

The in vitro activities of the novel fungal Cyp51 inhibitor VT-1129 were evaluated against a large panel of Cryptococcus neoformans and Cryptococcus gattii isolates. VT-1129 demonstrated potent activities against both Cryptococcus species as demonstrated by low MIC50and MIC90values. For C. gattii, the in vitro potency was maintained against all genotypes. In addition, significantly lower geometric mean MICs were observed for VT-1129 than for fluconazole against C. neoformans, including isolates with reduced fluconazole susceptibility.

Idioma originalEnglish (US)
Páginas (desde-hasta)2528-2531
Número de páginas4
PublicaciónAntimicrobial agents and chemotherapy
Volumen60
N.º4
DOI
EstadoPublished - abr 2016

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Huella

Profundice en los temas de investigación de 'The investigational fungal Cyp51 inhibitor VT-1129 demonstrates potent in vitro activity against cryptococcus neoformans and cryptococcus gattii'. En conjunto forman una huella única.

Citar esto